bioAffinity Technologies Completes Approximately $4 Million Financing
+2 new sources since this summary was written
bioAffinity Technologies completed a registered direct offering and concurrent private placement with an institutional investor on October 9, 2026, raising approximately $4 million. The financing included 116,545 common shares at $6.122, 536,836 pre-funded warrants at $6.115, and warrants for up to 980,072 shares at $6.122. Net proceeds are intended for working capital and general corporate purposes, including support for CyPath Lung sales.
Why it matters
The transaction gives bioAffinity additional funding but creates potential dilution through the issued securities and warrants. The company plans to use the proceeds for working capital and commercialization activities, while the registration rights agreement is intended to provide investors resale liquidity.
Key facts
- 1The financing raised approximately $4 million and included 116,545 common shares priced at $6.122 and 536,836 pre-funded warrants priced at $6.115. tradingview.com
- 2The concurrent private placement included warrants to purchase 980,072 common shares at an exercise price of $6.122. tradingview.com
- 3The warrants are exercisable for five years following stockholder approval. tradingview.com
- 4WallachBeth Capital acted as exclusive placement agent and received a 7.5% cash fee, a $70,000 expense reimbursement, and a warrant covering 19,602 shares. tradingview.com
- 5The offering was completed on October 9, 2026, after being agreed with an institutional investor. tradingview.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.